Oban BioPharma
1 known investors
Oban develops allosteric GPCR-targeted therapeutics for metabolic and CNS diseases using computational structural analysis and AI-based druggability screening. The company focuses on creating medicines with potentially fewer side effects than traditional GPCR drugs.
AI & Machine LearningBiotechDeep Tech